梅特福林停止和痴呆症发生率
Scott C Zimmerman1, Erin L Ferguson1, Vidhu Choudhary2
1Department of Epidemiology and Statistics, University of California, San Francisco.
JAMA network open
|October 25, 2023
概括
与脏问题无关的早期停止甲素与更高的痴呆风险有关. 这表明甲福明可以在糖尿病患者中提供对痴呆症的保护.
科学领域:
- 老年学是指老年学的学科.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 之前的研究表明,甲福明可能会降低痴呆症发病率.
- 然而,由于糖尿病的严重程度和处方模式,这些关联可能会被混.
- 梅特福林的停止通常是由于功能障碍,但也因为其他不良影响而发生.
研究的目的:
- 调查因与脏无关的原因停止使用甲胺与痴呆症发病率之间的联系.
- 探索甲胺在糖尿病管理中的潜在神经保护作用.
主要方法:
- 北加利福尼亚州凯泽永久医院的一项队列研究包括没有先前脏疾病的甲福林使用者.
- 12,220名早期终结者 (停止使用甲福林,功能正常) 与常规使用者进行了比较.
- 生存和调解模型分析了痴呆症发病率,调整了混因素,并评估了血糖控制的作用.
主要成果:
- 早期停止使用甲福明与21%增加患痴呆症的风险相关 (HR,1.21;95% CI,1.12-1.30).
- 这种关联似乎在很大程度上独立于HbA1c水平或终止后胰岛素使用的变化.
- 调解分析表明,血糖控制变化对观察到的关联的贡献很小.
结论:
- 除了功能障碍之外的其他原因,停止服用甲福林与更高的痴呆症发病率有关.
- 这些发现支持metformin可能对痴呆症有保护作用的假设.
- 对临床实践的影响 关于在糖尿病管理和痴呆症预防中使用甲胺.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
01:30Dementia
120
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
120
01:23Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
01:15Diabetes: Symptoms, Diagnosis, and Complications
557
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
557